AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer

Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2

Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V. A., Manegold, C., Scagliotti, G. V., Rosell, R., Oliff, I. A., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,701

Oncogenically active MYD88 mutations in human lymphoma

Ngo, V. N., Young, R. M., Schmitz, R., Jhavar, S. G., Xiao, W., Lim, K., Kohlhammer, H., Xu, W., Yang, Y., Zhao, H., et al. (2010) · Nature · doi:10.1038/nature09671 · Cited by 1,560

IHC Profiler: An Open Source Plugin for the Quantitative Evaluation and Automated Scoring of Immunohistochemistry Images of Human Tissue Samples

Varghese, F., Bukhari, A. B., Malhotra, R., & De, A. (2014) · PLoS ONE · doi:10.1371/journal.pone.0096801 · Cited by 1,318

Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome

Minegishi, Y., Saitō, M., Tsuchiya, S., Tsuge, I., Takada, H., Hara, T., Kawamura, N., Ariga, T., Pašić, S., Stojković, O., et al. (2007) · Nature · doi:10.1038/nature06096 · Cited by 1,075

Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial

Raal, F. J., Santos, R. D., Blom, D. J., Marais, A. D., Charng, M., Cromwell, W. C., Lachmann, R., Gaudet, D., Tan, J. L., Chasan-Taber, S., et al. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60284-x · Cited by 934

Enhanced DNA-Binding Activity of a Stat3-Related Protein in Cells Transformed by the Src Oncoprotein

Yu, C.-L., Meyer, D. J., Campbell, G. S., Larner, A. C., Carter-Su, C., Schwartz, J., & Jove, R. (1995) · Science · doi:10.1126/science.7541555 · Cited by 931

Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis

Shaw, A. T., Yeap, B. Y., Solomon, B., Riely, G. J., Gainor, J. F., Engelman, J. A., Shapiro, G. I., Costa, D. B., Ou, S. I., Butaney, M., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70232-7 · Cited by 897

Oncogene Addiction

Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805

SOCS-1, a negative regulator of the JAK/STAT pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity

Yoshikawa, H., Matsubara, K., Qian, G.-S., Jackson, P. E., Groopman, J. D., Manning, J. E., Harris, C. C., & Herman, J. G. (2001) · Nature Genetics · doi:10.1038/ng0501-29 · Cited by 724

Mitochondrial STAT3 Supports Ras-Dependent Oncogenic Transformation

Gough, D. J., Corlett, A., Schlessinger, K., Wegrzyn, J., Larner, A. C., & Levy, D. E. (2009) · Science · doi:10.1126/science.1171721 · Cited by 716

Targeting the IL-6/JAK/STAT3 signalling axis in cancer

Johnson, D. E., O'Keefe, R. A., & Grandis, J. R. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.8 · Cited by 3,110

Long Noncoding RNAs in Cancer Pathways

Schmitt, A. M., & Chang, H. Y. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.03.010 · Cited by 3,022

Targeting apoptosis in cancer therapy

Carneiro, B. A., & El‐Deiry, W. S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0341-y · Cited by 2,676

Advances in oligonucleotide drug delivery

Roberts, T. C., Langer, R., & Wood, M. J. A. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0075-7 · Cited by 2,121

Tumor microenvironment as a therapeutic target in cancer

Xiao, Y. Q., & Yu, D. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107753 · Cited by 2,008

Turning foes to friends: targeting cancer-associated fibroblasts

Chen, X., & Song, E. (2018) · Nature Reviews Drug Discovery · doi:10.1038/s41573-018-0004-1 · Cited by 1,929

The role of non-coding RNAs in oncology

Slack, F. J., & Chinnaiyan, A. M. (2019) · Cell · doi:10.1016/j.cell.2019.10.017 · Cited by 1,619

Recent insights into targeting the IL-6 cytokine family in inflammatory diseases and cancer

Jones, S. A., & Jenkins, B. J. (2018) · Nature Reviews Immunology · doi:10.1038/s41577-018-0066-7 · Cited by 1,102

Targeting STAT3 in Cancer Immunotherapy

Zou, S., Tong, Q., Liu, B., Huang, W., Tian, Y., & Fu, X. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01258-7 · Cited by 1,109

RNA-Targeted Therapeutics

Crooke, S. T., Witztum, J. L., Bennett, C. F., & Baker, B. F. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.004 · Cited by 841

Antisense technology: an overview and prospectus

Crooke, S. T., Baker, B. F., Crooke, R. M., & Liang, X.-H. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00162-z · Cited by 775

A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo

Bai, L., Zhou, H., Xu, R., Zhao, Y., Chinnaswamy, K., McEachern, D., Chen, J., Yang, C.-Y., Liu, Z., Wang, M., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.10.002 · Cited by 652

Long noncoding RNAs in cancer metastasis

Liu, S. J., Dang, H. X., Lim, D. A., Feng, F. Y.-C., & Maher, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00353-1 · Cited by 653

Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs

Shen, X., & Corey, D. R. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx1239 · Cited by 654

Therapeutic Targeting of Long Non-Coding RNAs in Cancer

Arun, G., Diermeier, S. D., & Spector, D. L. (2018) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2018.01.001 · Cited by 625

Myeloid-Derived Suppressor Cells Hinder the Anti-Cancer Activity of Immune Checkpoint Inhibitors

Weber, R., Fleming, V., Hu, X., Nagibin, V. S., Groth, C., Altevogt, P., Utikal, J. S., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01310 · Cited by 546

Therapeutically exploiting STAT3 activity in cancer — using tissue repair as a road map

Huynh, J., Chand, A. L., Gough, D. J., & Ernst, M. (2018) · Nature reviews. Cancer · doi:10.1038/s41568-018-0090-8 · Cited by 517

Long Noncoding RNA in Cancer: Wiring Signaling Circuitry

Lin, C., & Yang, L. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2017.11.008 · Cited by 488

Emerging roles of lncRNA in cancer and therapeutic opportunities.

Jiang, M., Ni, J., Cui, W., Wang, B., & Zhuo, W. (2019) · PubMed · Cited by 502

Targeting cytokine and chemokine signaling pathways for cancer therapy

Yi, M., Li, T., Niu, M., Zhang, H., Wu, Y., Wu, K., & Dai, Z. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01868-3 · Cited by 528

Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

Wu, Y., Yi, M., Niu, M., Mei, Q., & Wu, K. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01657-y · Cited by 475

The Medicinal Chemistry of Therapeutic Oligonucleotides

Wan, W. B., & Seth, P. P. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00551 · Cited by 445

Pharmacology of Antisense Drugs

Bennett, C. F., Baker, B. F., Pham, N. C., Swayze, E. E., & Geary, R. S. (2016) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010716-104846 · Cited by 445

STAT3 as a potential therapeutic target in triple negative breast cancer: a systematic review

Qin, J., Li, Y., Zhang, J., & Zhang, W. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1206-z · Cited by 424

Alternative‐splicing defects in cancer: Splicing regulators and their downstream targets, guiding the way to novel cancer therapeutics

Urbanski, L. M., Leclair, N. K., & Anczuków, O. (2018) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1476 · Cited by 393

New Modalities for Challenging Targets in Drug Discovery

Valeur, E., Guéret, S. M., Adihou, H., Gopalakrishnan, R., Lemurell, M., Waldmann, H., Grossmann, T. N., & Plowright, A. T. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201611914 · Cited by 394

“Do We Know Jack” About JAK? A Closer Look at JAK/STAT Signaling Pathway

Bousoik, E., & Aliabadi, H. M. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00287 · Cited by 395

Non-coding RNA in hepatocellular carcinoma: Mechanisms, biomarkers and therapeutic targets

Klingenberg, M., Matsuda, A., Diederichs, S., & Patel, T. C. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2017.04.009 · Cited by 355

Antisense technology: A review

Crooke, S. T., Liang, X., Baker, B. F., & Crooke, R. M. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.100416 · Cited by 350

STAT3 activation through IL-6/IL-11 in cancer-associated fibroblasts promotes colorectal tumour development and correlates with poor prognosis

Heichler, C., Koop, K., Schmied, A., Geppert, C. I., Schmid, B., Wirtz, S. J., Thoma, O., Kramer, V., Waldner, M. J., Büttner, C., et al. (2019) · Gut · doi:10.1136/gutjnl-2019-319200 · Cited by 330

Targeting Janus Kinases and Signal Transducer and Activator of Transcription 3 To Treat Inflammation, Fibrosis, and Cancer: Rationale, Progress, and Caution

Bharadwaj, U., Kasembeli, M. M., Robinson, P., & Tweardy, D. J. (2020) · Pharmacological Reviews · doi:10.1124/pr.119.018440 · Cited by 314

Recent progress in non-native nucleic acid modifications

McKenzie, L. K., El-Khoury, R., Thorpe, J. D., Damha, M. J., & Hollenstein, M. (2021) · Chemical Society Reviews · doi:10.1039/d0cs01430c · Cited by 306

The powerful world of antisense oligonucleotides: From bench to bedside

Quéméner, A. M., Bachelot, L., Forestier, A., Donnou‐Fournet, E., Gilot, D., & Galibert, M. (2020) · Wiley Interdisciplinary Reviews - RNA · doi:10.1002/wrna.1594 · Cited by 284

Unraveling the complexity of STAT3 in cancer: molecular understanding and drug discovery

Hu, Y., Dong, Z., & Liu, K. (2024) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-024-02949-5 · Cited by 307

STAT3 antisense oligonucleotide AZD9150 in a subset of patients with heavily pretreated lymphoma: results of a phase 1b trial

Reilley, M. J., McCoon, P., Cook, C., Lyne, P., Kurzrock, R., Kim, Y., Woessner, R., Younes, A., Nemunaitis, J., Fowler, N., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0436-5 · Cited by 245

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Kamerkar, S., Leng, C., Burenkova, O. V., Jang, S. C., McCoy, C., Zhang, K. X., Dooley, K., Kasera, S., Zi, T., Sisó, S., et al. (2022) · Science Advances · doi:10.1126/sciadv.abj7002 · Cited by 266

Fibroblast heterogeneity in tumor micro-environment: Role in immunosuppression and new therapies

Mhaidly, R., & Mechta‐Grigoriou, F. (2020) · Seminars in Immunology · doi:10.1016/j.smim.2020.101417 · Cited by 267

Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma

Tiacci, E., Ladewig, E., Schiavoni, G., Penson, A., Fortini, E., Pettirossi, V., Wang, Y., Rosseto, A. S., Venanzi, A., Vlasevska, S., et al. (2018) · Blood · doi:10.1182/blood-2017-11-814913 · Cited by 244

Structure-Based Discovery of SD-36 as a Potent, Selective, and Efficacious PROTAC Degrader of STAT3 Protein

Zhou, H., Bai, L., Xu, R., Zhao, Y., Chen, J., McEachern, D., Chinnaswamy, K., Wen, B., Dai, L., Kumar, P., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01530 · Cited by 233

IL-6/STAT3 Is a Promising Therapeutic Target for Hepatocellular Carcinoma

Xu, J., Lin, H., Wu, G., Zhu, M., & Li, M. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.760971 · Cited by 228

Do STAT3 inhibitors have potential in the future for cancer therapy?

Wong, A. L. A., Hirpara, J. L., Pervaiz, S., Eu, J. Q., Sethi, G., & Goh, B.-C. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1351941 · Cited by 227

CD44+ Cells in Head and Neck Squamous Cell Carcinoma Suppress T-Cell–Mediated Immunity by Selective Constitutive and Inducible Expression of PD-L1

Lee, Y., Shin, J. H., Longmire, M. R., Wang, H., Kohrt, H. E. K., Chang, H. Y., & Sunwoo, J. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2665 · Cited by 225

JAK-STAT signaling in cancer: From cytokines to non-coding genome

Pěnčík, J., Pham, H. T. T., Schmoellerl, J., Javaheri, T., Schlederer, M., Čulig, Z., Merkel, O., Moriggl, R., Grebien, F., & Kenner, L. (2016) · Cytokine · doi:10.1016/j.cyto.2016.06.017 · Cited by 221

LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription

Xiu, B., Chi, Y., Liu, L., Chi, W., Zhang, Q., Chen, J., Guo, R., Si, J., Li, L., Xue, J., et al. (2019) · Molecular Cancer · doi:10.1186/s12943-019-1115-y · Cited by 212

EMT-Mediated Acquired EGFR-TKI Resistance in NSCLC: Mechanisms and Strategies

Zhu, X., Chen, L., Liu, L., & Niu, X. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01044 · Cited by 211

Targeting and engineering long non-coding RNAs for cancer therapy

Coan, M., Haefliger, S., Ounzain, S., & Johnson, R. (2024) · Nature Reviews Genetics · doi:10.1038/s41576-024-00693-2 · Cited by 210

The JAK/STAT3 axis: A comprehensive drug target for solid malignancies

Huynh, J., Etemadi, N., Hollande, F., Ernst, M., & Büchert, M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.06.001 · Cited by 201

Targeting Cancer Stem Cells in Triple-Negative Breast Cancer

Park, S., Choi, J., & Nam, J. (2019) · Cancers · doi:10.3390/cancers11070965 · Cited by 195

Mechanisms of Macrophage Plasticity in the Tumor Environment: Manipulating Activation State to Improve Outcomes

Ricketts, T. D., Prieto‐Domínguez, N., Gowda, P. S., & Ubil, E. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.642285 · Cited by 186

Aberrant RNA Splicing in Cancer and Drug Resistance

Wang, B., & Lee, N. (2018) · Cancers · doi:10.3390/cancers10110458 · Cited by 183

Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS

Ross, S. J., Revenko, A. S., Hanson, L. L., Ellston, R., Staniszewska, A., Whalley, N., Pandey, S. K., Revill, M., Rooney, C., Buckett, L. K., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal5253 · Cited by 177

JAK-STAT-mediated chronic inflammation impairs cytotoxic T lymphocyte activation to decrease anti-PD-1 immunotherapy efficacy in pancreatic cancer

Lu, C., Talukder, A. M., Savage, N. M., Singh, N., & Liu, K. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1291106 · Cited by 177

Insights into Biological Role of LncRNAs in Epithelial-Mesenchymal Transition

Cheng, J.-T., Wang, L., Wang, H., Tang, F.-R., Cai, W.-Q., Sethi, G., Xin, H.-W., & Ma, Z. (2019) · Cells · doi:10.3390/cells8101178 · Cited by 173

STAT3 pathway in cancers: Past, present, and future

Wang, H., Man, Q., Huo, F., Gao, X., Lin, H., Li, S.-R., Wang, J., Su, F., Cai, L., Shi, Y., et al. (2022) · MedComm · doi:10.1002/mco2.124 · Cited by 175

Targeting cancer‐related inflammation in the era of immunotherapy

Nakamura, K., & Smyth, M. J. (2016) · Immunology and Cell Biology · doi:10.1038/icb.2016.126 · Cited by 164

Translational and clinical advances in JAK-STAT biology: The present and future of jakinibs

Gadina, M., Johnson, C., Schwartz, D. M., Bonelli, M. M., Hasni, S., Kanno, Y., Changelian, P. S., Laurence, A. D. J., & O’Shea, J. J. (2018) · Journal of Leukocyte Biology · doi:10.1002/jlb.5ri0218-084r · Cited by 162

STAT3 Modulation of Regulatory T Cells in Response to Radiation Therapy in Head and Neck Cancer

Oweida, A., Darragh, L. B., Phan, A. V., Binder, D. C., Bhatia, S., Mueller, A. C., Court, B. V., Milner, D. C., Raben, D., Woessner, R. D., et al. (2019) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djz036 · Cited by 162

RNA-targeted therapeutics in cancer clinical trials: Current status and future directions

Barata, P. C., Sood, A. K., & Hong, D. S. (2016) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2016.08.004 · Cited by 153

Long Noncoding RNA and Epithelial Mesenchymal Transition in Cancer

Gugnoni, M., & Ciarrocchi, A. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20081924 · Cited by 149

Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies

Li, Y.-R., Fang, Y., Lyu, Z., Zhu, Y., & Yang, L. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04575-9 · Cited by 168

Clinical landscape of macrophage-reprogramming cancer immunotherapies

Rannikko, J. H., & Hollmén, M. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02715-6 · Cited by 169

Mitochondrial Stat3, the need for design thinking

Yang, R., & Rincon, M. (2016) · International Journal of Biological Sciences · doi:10.7150/ijbs.15153 · Cited by 147

YY1 regulates cancer cell immune resistance by modulating PD-L1 expression

Hays, E., & Bonavida, B. (2019) · Drug Resistance Updates · doi:10.1016/j.drup.2019.04.001 · Cited by 145

Image-based detection and targeting of therapy resistance in pancreatic adenocarcinoma

Fox, R. G., Lytle, N. K., Jaquish, D. V., Park, F. D., Ito, T., Bajaj, J., Koechlein, C. S., Zimdahl, B., Yano, M., Kopp, J. L., et al. (2016) · Nature · doi:10.1038/nature17988 · Cited by 142

STAT3: An Emerging Therapeutic Target for Hepatocellular Carcinoma

Lee, C., & Cheung, S. (2019) · Cancers · doi:10.3390/cancers11111646 · Cited by 148

Non-coding RNAs: the riddle of the transcriptome and their perspectives in cancer

Diamantopoulos, M. A., Tsiakanikas, P., & Scorilas, A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2018.06.10 · Cited by 139

The Role of Signal Transducer and Activator of Transcription 3 (STAT3) and Its Targeted Inhibition in Hematological Malignancies

Arora, L., Kumar, A. P., Arfuso, F., Chng, W. J., & Sethi, G. (2018) · Cancers · doi:10.3390/cancers10090327 · Cited by 124

The Interaction of Phosphorothioate-Containing RNA Targeted Drugs with Proteins Is a Critical Determinant of the Therapeutic Effects of These Agents

Crooke, S. T., Seth, P. P., Vickers, T. A., & Liang, X. (2020) · Journal of the American Chemical Society · doi:10.1021/jacs.0c04928 · Cited by 131

STAT3 in Tumor-Associated Myeloid Cells: Multitasking to Disrupt Immunity

Su, Y., Banerjee, S., White, S. V., & Kortylewski, M. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19061803 · Cited by 125

Immune Checkpoint Inhibition in Head and Neck Cancer

Forster, M. D., & Devlin, M.-J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00310 · Cited by 123

Stem and progenitor cell alterations in myelodysplastic syndromes

Shastri, A., Will, B., Steidl, U. G., & Verma, A. K. (2017) · Blood · doi:10.1182/blood-2016-10-696062 · Cited by 123

Pivotal Role of STAT3 in Shaping Glioblastoma Immune Microenvironment

Piperi, C., Papavassiliou, K. A., & Papavassiliou, A. G. (2019) · Cells · doi:10.3390/cells8111398 · Cited by 120

Structural Understanding of Interleukin 6 Family Cytokine Signaling and Targeted Therapies: Focus on Interleukin 11

Metcalfe, R. D., Putoczki, T. L., & Griffin, M. D. W. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01424 · Cited by 116

The role of STAT3 in glioblastoma progression through dual influences on tumor cells and the immune microenvironment

Chang, N., Ahn, S. H., Kong, D., Lee, H. W., & Nam, D. (2017) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2017.01.004 · Cited by 117

Antisense oligonucleotides: absorption, distribution, metabolism, and excretion

Shadid, M., Badawi, M. A., & Abulrob, A. (2021) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2021.1992382 · Cited by 123

A Positive Feedback Loop of AKR1C3-Mediated Activation of NF-κB and STAT3 Facilitates Proliferation and Metastasis in Hepatocellular Carcinoma

Zhou, Q., Tian, W., Jiang, Z., Huang, T., Ge, C., Liu, T., Zhao, F., Chen, T., Cui, Y., Li, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2480 · Cited by 112

Enhancing immunotherapy response in melanoma: myeloid-derived suppressor cells as a therapeutic target

Kurt, F. G. Ö., Lasser, S., Arkhypov, I., Utikal, J. S., & Umansky, V. (2023) · Journal of Clinical Investigation · doi:10.1172/jci170762 · Cited by 111

STAT3 Pathway in Gastric Cancer: Signaling, Therapeutic Targeting and Future Prospects

Ashrafizadeh, M., Zarrabi, A., Orouei, S., Zarrin, V., Moghadam, E. R., Zabolian, A., Mohammadi, S., Hushmandi, K., Gharehaghajlou, Y., Makvandi, P., et al. (2020) · Biology · doi:10.3390/biology9060126 · Cited by 109

Targeting STAT3 in cancer and autoimmune diseases

Gharibi, T., Babaloo, Z., Hosseini, A., Abdollahpour‐Alitappeh, M., Hashemi, V., Marofi, F., Nejati‐Koshki, K., & Baradaran, B. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173107 · Cited by 105

Antisense drug discovery and development technology considered in a pharmacological context

Crooke, S. T., Liang, X., Crooke, R. M., Baker, B. F., & Geary, R. S. (2020) · Biochemical Pharmacology · doi:10.1016/j.bcp.2020.114196 · Cited by 109

Targeting STAT3 signaling in kidney disease

Pace, J. A., Paladugu, P., Das, B. C., He, C., & Mallipattu, S. K. (2019) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00034.2019 · Cited by 105

STAT3: Versatile Functions in Non-Small Cell Lung Cancer

Mohrherr, J., Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · Cancers · doi:10.3390/cancers12051107 · Cited by 107

Antisense oligonucleotide treatment ameliorates IFN-γ–induced proteinuria in APOL1-transgenic mice

Aghajan, M., Booten, S. L., Althage, M., Hart, C. E., Ericsson, A., Maxvall, I., Ochaba, J., Menschik-Lundin, A., Hartleib, J., Kuntz, S., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.126124 · Cited by 102

Impacts and mechanisms of alternative mRNA splicing in cancer metabolism, immune response, and therapeutics

Qiu, P., Zhou, Y., Oyang, L., Wu, N., Tang, Y., Su, M., Luo, X., Wang, Y., Sheng, X., Ma, J., et al. (2021) · Molecular Therapy · doi:10.1016/j.ymthe.2021.11.010 · Cited by 109

Differential uptake, kinetics and mechanisms of intracellular trafficking of next-generation antisense oligonucleotides across human cancer cell lines

Linnane, E., Davey, P. R. J., Zhang, P., Puri, S., Edbrooke, M. R., Chiarparin, E., Revenko, A. S., MacLeod, A. R., Norman, J. C., & Ross, S. J. (2019) · Nucleic Acids Research · doi:10.1093/nar/gkz214 · Cited by 102

MaTAR25 lncRNA regulates the Tensin1 gene to impact breast cancer progression

Chang, K.-C., Diermeier, S. D., Yu, A. T., Brine, L., Russo, S., Bhatia, S., Alsudani, H., Kostroff, K. M., Bhuiya, T. A., Brogi, E., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-20207-y · Cited by 98

The revival of CpG oligonucleotide-based cancer immunotherapies

Adamus, T., & Kortylewski, M. (2018) · Współczesna Onkologia · doi:10.5114/wo.2018.73887 · Cited by 100

RNA-based therapies: A cog in the wheel of lung cancer defense

Κhan, P., Siddiqui, J. A., Lakshmanan, I., Ganti, A. K., Salgia, R., Jain, M., Batra, S. K., & Nasser, M. W. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01338-2 · Cited by 104

Clinical Applications of Single-Stranded Oligonucleotides: Current Landscape of Approved and In-Development Therapeutics

Scharner, J., & Aznarez, I. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.12.022 · Cited by 96

Antisense STAT3 inhibitor decreases viability of myelodysplastic and leukemic stem cells

Shastri, A., Choudhary, G. S., Teixeira, M., Gordon-Mitchell, S., Ramachandra, N., Bernard, L., Bhattacharyya, S., Lopez, R., Pradhan, K., Giricz, O., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci120156 · Cited by 95

Sorafenib combined with STAT3 knockdown triggers ER stress-induced HCC apoptosis and cGAS-STING-mediated anti-tumor immunity

Wang, X., Hu, R., Song, Z., Zhao, H., Pan, Z., Feng, Y., Yu, Y., Han, Q., & Zhang, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215880 · Cited by 92

Direct targeting of FOXP3 in Tregs with AZD8701, a novel antisense oligonucleotide to relieve immunosuppression in cancer

Revenko, A. S., Carnevalli, L. S., Sinclair, C., Johnson, B., Peter, A., Taylor, M. A., Hettrick, L. A., Chapman, M., Klein, S., Solanki, A., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003892 · Cited by 93

STAT3 inhibitor Napabucasin abrogates MDSC immunosuppressive capacity and prolongs survival of melanoma-bearing mice

Bitsch, R., Kurzay, A., Kurt, F. G. Ö., Torre, C. D. L., Lasser, S., Lepper, A., Siebenmorgen, A., Müller, V. A., Altevogt, P., Utikal, J. S., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004384 · Cited by 88

Myeloid cell–targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell–mediated immunity

Moreira, D., Sampath, S., Won, H., White, S. V., Su, Y., Alcantara, M. B., Wang, C., Lee, P. P., Maghami, E. G., Massarelli, E., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137001 · Cited by 87

Therapeutic targeting of the crosstalk between cancer-associated fibroblasts and cancer stem cells.

Huang, T., Guan, X., & Fu, L. (2019) · Europe PMC (PubMed Central) · Cited by 85

Radio Signals from Live Cells: The Coming of Age of In-Cell Solution NMR

Luchinat, E., Cremonini, M., & Banci, L. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00790 · Cited by 86

The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression

Sun, C., Li, S., Zhang, F., Zhang, Y., Zuo, Z., Xi, Y., Wang, L., & Li, D. (2016) · Molecular Therapy — Nucleic Acids · doi:10.1038/mtna.2016.96 · Cited by 84

Glioma-targeted delivery of exosome-encapsulated antisense oligonucleotides using neural stem cells

Adamus, T., Hung, C.-Y., Yu, C., Kang, E. Y., Hammad, M., Flores, L., Nechaev, S., Zhang, Q., Gonzaga, J. M., Muthaiyah, K., et al. (2021) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2021.12.029 · Cited by 84

Luteolin selectively kills STAT3 highly activated gastric cancer cells through enhancing the binding of STAT3 to SHP-1

Song, S., Su, Z., Xu, H., Niu, M., Chen, X., Min, H., Zhang, B., Sun, G., Xie, S., Wang, H., et al. (2017) · Cell Death and Disease · doi:10.1038/cddis.2017.38 · Cited by 82

Engineering Gene Therapy: Advances and Barriers

Shahryari, A., Burtscher, I., Nazari, Z., & Lickert, H. (2021) · Advanced Therapeutics · doi:10.1002/adtp.202100040 · Cited by 87

Abstract LB-227: Preclinical pharmacology and clinical efficacy of AZD9150 (ISIS-STAT3Rx), a potent next-generation antisense oligonucleotide inhibitor of STAT3

Hong, D. S., Kim, Y., Younes, A., Nemunaitis, J. J., Fowler, N. H., Hsu, J., Zhou, T., Fayad, L., Zhang, N., Piha-Paul, S. A., et al. (2014) · Cancer Research · doi:10.1158/1538-7445.am2014-lb-227 · Cited by 5

Abstract LB-317: Potent in vivo pharmacology of AZD9150, a next-generation, constrained ethyl-modified antisense oligonucleotide targeting STAT3 in multiple preclinical cancer models.

Kim, Y., Hsu, J., Zhou, T., Zhang, N., Woessner, R. D., Nadella, M. V. P., Lawson, D., Reimer, C., He, G., Schmidt, J., et al. (2013) · Cancer Research · doi:10.1158/1538-7445.am2013-lb-317 · Cited by 2

Blocking transcription in tumors, STAT

Nusinovich, Y. A. (2015) · Science Signaling · doi:10.1126/scisignal.aad9035

Strong pharmacological activity of locally administered next-generation antisense oligonucleotides (ASOs) in orthotopic lung cancer mouse models

Jo, M., Schmidt, J., Zhou, T., Wu, X., Crosby, J. R., Brand, E., Kim, Y., & MacLeod, A. R. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.12.043 · Cited by 1

Abstract C136: Exploring the functional contribution of STAT3 activity in tumor and tumor-associated stromal cells with species-selective generation 2.5 antisense oligonucleotides in preclinical cancer models.

Hsu, J., He, G., Bhattacharjee, G., Zhou, T., Kim, Y., Monia, B. P., & MacLeod, R. (2011) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.targ-11-c136